Founded in 2006, Emeryville, CA headquartered Eureka Therapeutics operates a biotechnology platform aimed at offering therapeutic antibody treatments. The company’s biotechnology innovation is focused on improving the safety profile of T cell therapies and developing novel varieties for the treatment of solid tumors, enabling clients to utilize a pipeline of novel cancer therapeutics, targeting intracellular oncogenes as well as cell-surface antigens.